Welcome to our dedicated page for Joint SEC filings (Ticker: JYNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the metrics that really move Joint Corp—clinic count growth, franchise royalties, or membership churn? This page brings every SEC disclosure together so you can stop hunting and start understanding. Whether you need the Joint Corp insider trading Form 4 transactions or the latest Joint Corp quarterly earnings report 10-Q filing, Stock Titan delivers them the moment they hit EDGAR.
Our AI engine reads each document line-by-line and serves plain-English answers. Think of it as "Joint Corp SEC filings explained simply"—from a 300-page 10-K to a one-page 8-K. Click any filing type below and you’ll see auto-generated key points, ratio calculations, and trend charts:
- Joint Corp annual report 10-K simplified—franchise economics, clinic openings, risk factors
- Joint Corp Form 4 insider transactions real-time—alerts on executive buys and sells
- Joint Corp proxy statement executive compensation—bonus targets tied to same-store sales
- Joint Corp 8-K material events explained—new market entries or leadership updates
Need deeper context? Our "understanding Joint Corp SEC documents with AI" module cross-links sections so you can compare revenue per clinic across multiple quarters. For quick takeaways, the "Joint Corp earnings report filing analysis" highlights margin shifts and patient visit growth. Professionals monitoring Joint Corp executive stock transactions Form 4 can set real-time alerts to spot patterns before the market reacts.
Every document, every detail, always current—because informed decisions start with complete, clear data.
JOINT Corp (JYNT) entered a consent and third amendment to its existing credit agreement with JPMorgan Chase Bank, N.A. on
TheJoint operates a rapidly expanded clinic network, growing from eight clinics in 2010 to 967 clinics in operation as of December 31, 2024 and again reporting 967 locations (franchised or company-owned/managed) as of June 30, 2025 across 42 states and D.C. The company’s model emphasizes low-cost, appointment-free chiropractic care with membership plans, charging a 7.0% royalty and a 2.0% national marketing fee on franchised clinics and collecting an initial franchise fee of $39,900. In 2023 management began a plan to refranchise or sell most company-owned clinics and in Q3 2024 expanded that plan to market the full portfolio in geographic clusters. Clinical visits average 15–20 minutes for new patients and 5–7 minutes for returning patients. The prospectus contains customary forward-looking statements and references filings incorporated by reference.
Form 144 notice for The Joint Corp. (JYNT) reports a proposed sale of 12,000 shares of common stock via Raymond James on 08/29/2025 with an aggregate market value of $127,920. The filing shows the 12,000 shares were acquired through RSU vesting on multiple dates between 08/07/2021 and 05/25/2024, and that the planned sale equals the total of those vested RSUs. The issuer's outstanding shares are listed as 15,340,000, and the filing also discloses a prior sale by the same person of 20,000 common shares on 08/22/2025 for gross proceeds of $215,000. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
The company disclosed the departure of its Chief Financial Officer, Mr. Singleton, whose role ceased effective June 9, 2025. The company and Mr. Singleton entered a separation agreement dated August 22, 2025 that includes a general release and a revocation period. If not revoked, the agreement provides Separation Benefits: a cash payment equal to six months of base salary, a cash payment for accumulated time off of $36,193.99, an additional cash payment of $15,000, reimbursement for accrued expenses per company policy, and payment of up to six months of COBRA health-insurance cost if elected. Outstanding equity awards will be governed by existing award agreements and plans and will not receive accelerated vesting under the Separation Agreement.
The filer submitted a Form 144 to notify a proposed sale of 20,000 common shares of The Joint Corp. (JYNT) through Raymond James & Associates on NASDAQ, with an aggregate market value of $215,000 and approximately 15,340,000 shares outstanding. The shares were acquired by the same person through two stock option exercises: 10,289 shares on 08/22/2025 and 9,711 shares on 08/25/2025, each paid in cash on the exercise dates. The filer reports no securities sold in the past three months. The form includes the routine certification that the seller is not aware of undisclosed material adverse information. Certain filer identification fields in the provided content are blank.
The reporting person, Christopher M. Grandpre, a director of The Joint Corp. (JYNT), purchased 10,000 shares of the issuer's common stock on 08/20/2025 at a weighted-average price of $10.4082 per share. After the reported acquisition, the reporting person beneficially owns 39,383 shares in total. The filing was signed by an attorney-in-fact on 08/22/2025. The footnote clarifies the reported price is a weighted average covering multiple purchases at prices ranging from $10.30 to $10.57, and the reporting person will provide breakdowns on request.
Charles E. Jobson filed an amended Schedule 13G reporting beneficial ownership of 1,075,994 shares of JOINT Corp common stock (CUSIP 47973J102), representing 7.01% of the class. The filing states Mr. Jobson has sole voting and sole dispositive power over all reported shares, and no shared voting or dispositive arrangements are reported. The document lists JOINT Corp's principal executive office in Scottsdale, Arizona, and Mr. Jobson's residence in Wellesley, Massachusetts. No group affiliations, subsidiaries, or holdings on behalf of others are reported, and certification language attests to the accuracy of the statement.
Christopher M. Grandpre, a director of The Joint Corp. (JYNT), reported two open-market purchases of the issuer's common stock in mid-August 2025. The filing shows a purchase of 14,388 shares on 08/15/2025 at a weighted average price of $10.8793 and a subsequent purchase of 10,000 shares on 08/18/2025 at a weighted average price of $10.6978. Following these transactions he beneficially owned 29,383 shares as a direct owner. The filing was submitted under a Form 4 and signed by an attorney-in-fact on 08/19/2025. No derivative transactions, dispositions, or additional contextual details about the purpose of the purchases are provided in this document.
FAQ
What is the current stock price of Joint (JYNT)?
What is the market cap of Joint (JYNT)?
